StocksMediumUpdated•Originally published 3 November 2026•Updated 3 November 2026•
1 min read
bioMérieux Q3 Revenue Beats Estimates at €1.04 Billion
Key Facts
1bioMérieux reported Q3 2026 revenue of €1.04 billion, exceeding analyst consensus estimates.
2The company reaffirmed its full-year financial targets for 2026.
bioMérieux reported Q3 2026 revenue of €1.04 billion, exceeding analyst consensus estimates. Benzinga reported that the company reaffirmed its full-year financial targets for 2026, signaling operational resilience in its diagnostic solutions business.
BIM.PA closed at €90.4 on November 2, 2026, prior to the release of these results. The stock traded between a low of €89.3 and a high of €91.8 during the November 2, 2026, session.
Latest Updates · 1
- Notable·
Update: bioMérieux attributed its organic sales beat in the third quarter of 2026 to a disease outbreak in the United States. This increased demand supported the company's strong financial performance in the U.S. market during the period.